nach oben

Erschienen in:

04.04.2019 | Review

Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis

verfasst von: Omar Saeed, Lori J. Bernstein, Rouhi Fazelzad, Mary Samuels, Lynn A. Burmeister, Lehana Thabane, Shereen Ezzat, David P. Goldstein, Jennifer Jones, Anna M. Sawka

Erschienen in: Journal of Cancer Survivorship | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Some thyroid cancer (TC) survivors experience cognitive symptoms.

Purpose

The purpose of this study is to perform a systematic literature review and meta-analysis comparing cognitive performance in TC survivors to controls.

Methods

We performed a seven-database electronic search and hand-search. We performed duplicate independent reviews and data abstraction. Random effects meta-analyses reported standardized mean differences (SMDs) with 95% confidence intervals (CIs), where a negative value implies worse performance in the TC group.

Results

We reviewed 1174 unique citations and 10 full-text papers. We included seven studies of 241 treated TC survivors and 273 controls. Cognitive function was statistically significantly worse in TC survivors in the following domains: Attention and Concentration (Digit Span Forwards) SMD − 0.37 (95% CI − 0.62, − 0.13, p = 0.003, four studies), Speed of Processing (Trail Making A) SMD − 0.36 (95% CI − 0.66, − 0.05, p = 0.022, four studies), and Language (Controlled Oral Word Association [COWAT]-Categories) SMD − 0.97 (95% − 1.31, − 0.64, p < 0.001, two studies). Executive Function results varied: COWAT-Letters SMD − 0.60 (95% CI − 0.94, − 0.27, p < 0.001, two studies), Digit Span Backwards SMD − 0.40 (95% CI − 0.64, − 0.15, p = 0.002, four studies), and Trail Making B test SMD − 0.20 (95% CI − 0.51, 0.10, p = 0.191, four studies). Statistical heterogeneity limited the COWAT-Categories and Digit Span Backwards meta-analyses.

Conclusions

Cognitive function was worse in TC survivors in multiple domains. Limitations included few studies, potential confounding, and lack of prospective data.

Implications for Cancer Survivors

TC survivors may experience impairments in cognitive function and should report cognitive concerns to healthcare practitioners.

Nur mit Berechtigung zugänglich

La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136(9):2187–95.CrossRefPubMed

International Agency for Research on Cancer 2017 GLOBOCAN 2012: Estimated cancer incidence, mortality, and prevalence worldwide in 2012. Available at http://globocan.iarc.fr/Pages/fact_sheets_population.aspx Accessed July 18, 2018.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. for the American Thyroid Association 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefPubMedPubMedCentral

Rosenthal K. When cancer muddles the mind. 2009 New York Times. Available at: https://well.blogs.nytimes.com/2009/11/17/when-cancer-muddles-the-mind/ Accessed July 18, 2018.

Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, et al. Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force Symposium and Update since 2012. J Pain Symptom Manag. 2015;50(6):830–41.CrossRef

Ahles TA, Root JC. Cognitive effects of cancer and cancer treatments. Annu Rev Clin Psychol. 2018;14:425–51.CrossRefPubMedPubMedCentral

Bernstein LJ, McCreath GA, Komeylian Z, Rich JB. Cognitive impairment in breast cancer survivors treated with chemotherapy depends on control group type and cognitive domains assessed: a multilevel meta-analysis. Neurosci Biobehav Rev. 2017;83:417–28.CrossRefPubMed

Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6.CrossRefPubMed

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.CrossRefPubMed

10.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;73:177–88.CrossRef

11.

Cochrane WG. The combination of estimates from different experiments. Biometrics. 1954;101:101–29.CrossRef

12.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;3277414:557–60.CrossRef

13.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;3157109:629–34.CrossRef

14.

Burmeister LA, Ganguli M, Dodge HH, Toczek T, DeKosky ST, Nebes RD. Hypothyroidism and cognition: preliminary evidence for a specific defect in memory. Thyroid. 2001;11(12):1177–85.CrossRefPubMed

15.

Samuels MH, Kolobova I, Smeraglio A, Peters D, Janowsky JS, Schuff KG. The effects of levothyroxine replacement or suppressive therapy on health status, mood, and cognition. J Clin Endocrinol Metab. 2014;99(3):843–51.CrossRefPubMedPubMedCentral

16.

Samuels MH, Kolobova I, Niederhausen M, Janowsky JS, Schuff KG. Effects of altering levothyroxine (L-T4) doses on quality of life, mood, and cognition in L-T4 treated subjects. J Clin Endocrinol Metab. 2018;103(5):1997–2008.CrossRefPubMedPubMedCentral

17.

Botella-Carretero JI, Galán JM, Caballero C, Sancho J, Escobar-Morreale HF. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2003;10(4):601–10.CrossRefPubMed

18.

Bunevicius R, Prange AJ. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol. 2000;3(2):167–74.CrossRefPubMed

19.

Constant EL, Adam S, Seron X, Bruyer R, Seghers A, Daumerie C. Anxiety and depression, attention, and executive functions in hypothyroidism. J Int Neuropsychol Soc. 2005;11(5):535–44.CrossRefPubMed

20.

Husson O, Haak HR, Buffart LM, Nieuwlaat WA, Oranje WA, Mols F, et al. Health-related quality of life and disease specific symptoms in long-term thyroid cancer survivors: a study from the population-based PROFILES registry. Acta Oncol. 2013;52(2):249–58.CrossRefPubMed

21.

Jaracz J, Kucharska A, Rajewska-Rager A, Lacka K. Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma. J Endocrinol Investig. 2012;35(8):760–5.

22.

Jung MS, Visovatti M. Post-treatment cognitive dysfunction in women treated with thyroidectomy for papillary thyroid carcinoma. Support Care Cancer. 2017;25(3):915–23.CrossRefPubMed

23.

Moon JH, Ahn S, Seo J, Han JW, Kim KM, Choi SH, et al. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2014;99(10):3782–9.CrossRefPubMed

24.

Li M, Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: a systematic review. Neurosci Biobehav Rev. 2018;92:304–17. https://doi.org/10.1016/j.neubiorev.2018.05.019.CrossRefPubMed

25.

Pierson C, Waite E, Pyykkonen B. A meta-analysis of the neuropsychological effects of chemotherapy in the treatment of childhood cancer. Pediatr Blood Cancer. 2016;63(11):1998–2003.CrossRefPubMed

26.

Edelstein K, D’agostino N, Bernstein LJ, Nathan PC, Greenberg ML, Hodgson DC, et al. Long-term neurocognitive outcomes in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2011;33(6):450–8.CrossRefPubMed

27.

Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, et al. Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2018;144:71–9.PubMed

28.

Harrison RA, Wefel JS. Neurocognitive function in adult cancer patients. Neurol Clin. 2018;36(3):653–74.CrossRefPubMed

29.

Lee PE, Tierney MC, Wu W, Pritchard KI, Rochon PA. Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. Breast Cancer Res Treat. 2016;158(3):407–20.CrossRefPubMed

30.

Mandelblatt JS, Small BJ, Luta G, Hurria A, Jim H, McDonald BC, et al. Cancer-related cognitive outcomes among older breast cancer survivors in the thinking and living with cancer study. J Clin Oncol. 2018;36(32):3211–22. https://doi.org/10.1200/JCO.18.00140.CrossRefPubMedCentral

31.

Liao KF, Lin CL, Lai SW. Nationwide case-control study examining the association between tamoxifen use and Alzheimer’s disease in aged women with breast cancer in Taiwan. Front Pharmacol. 2017;8:612.CrossRefPubMedPubMedCentral

32.

Sun LM, Chen HJ, Liang JA, Kao CH. Long-term use of tamoxifen reduces the risk of dementia: a nationwide population-based cohort study. QJM. 2016;109(2):103–9.CrossRefPubMed

33.

Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199(6):1417–25.CrossRefPubMed

34.

Morote J, Tabernero ÁJ, Álvarez Ossorio JL, Ciria JP, Domínguez-Escrig JL, Vázquez F, et al. ANAMEM Investigator Group. Cognitive function in patients with prostate cancer receiving luteinizing hormone-releasing hormone analogues: a prospective, observational, multicenter study. Int J Radiat Oncol Biol Phys. 2017;98(3):590–4.CrossRefPubMed

35.

Tae BS, Jeon BJ, Shin SH, Choi H, Bae JH, Park JY. Correlation of androgen deprivation therapy with cognitive dysfunction in patients with prostate cancer: a nationwide population-based study using the National Health Insurance Service Database. Cancer Res Treat 2018. doi: https://doi.org/10.4143/crt.2018.119.

36.

Deka R, Simpson DR, Bryant AK, Nalawade V, McKay R, Murphy JD, et al. Association of androgen deprivation therapy with dementia in men with prostate cancer who receive definitive radiation therapy. JAMA Oncol. 2018;4:1616. https://doi.org/10.1001/jamaoncol.2018.4423.CrossRefPubMedPubMedCentral

37.

McHugh DJ, Root JC, Nelson CJ, Morris MJ. Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: how much smoke and how much fire? Cancer. 2018;124(7):1326–34.CrossRefPubMed

38.

Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3:49–55.CrossRefPubMed

39.

Kao LT, Lin HC, Chung SD, Huang CY. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study. Asian J Androl. 2017;19(4):414–7.CrossRefPubMed

40.

Chung S, Lin H, Tsai M, Kao L, Huang C, Chen KC. Androgen deprivation therapy did not increase the risk of Alzheimer’s and Parkinson’s disease in patients with prostate cancer. Andrology. 2016;4:481–5.CrossRefPubMed

41.

Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L. Androgen deprivation therapy and the risk of dementia in patients with prostate cancer. J Clin Oncol. 2017;35:201–7.CrossRefPubMed

42.

Rieben C, Segna D, da Costa BR, Collet TH, Chaker L, Aubert CE, et al. Subclinical thyroid dysfunction and the risk of cognitive decline: a meta-analysis of prospective cohort studies. J Clin Endocrinol Metab. 2016;101(12):4945–54.CrossRefPubMedPubMedCentral

43.

Aubert CE, Bauer DC, da Costa BR, Feller M, Rieben C, Simonsick EM, et al. The association between subclinical thyroid dysfunction and dementia: The Health, Aging and Body Composition (Health ABC) Study. Clin Endocrinol. 2017;87(5):617–26.CrossRef

44.

Szlejf C, Suemoto CK, Santos IS, Lotufo PA, Haueisen Sander Diniz MF, Barreto SM, et al. Thyrotropin level and cognitive performance: baseline results from the ELSA-Brasil study. Psychoneuroendocrinology. 2018;87:152–8.CrossRefPubMed

45.

Peterson SJ, Cappola AR, Castro MR, Dayan CM, Farwell AP, Hennessey JV, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707–21.CrossRefPubMedPubMedCentral

46.

Regalbuto C, Maiorana R, Alagona C, Paola RD, Cianci M, Alagona G, et al. Effects of either LT4 monotherapy or LT4/LT3 combined therapy in patients totally thyroidectomized for thyroid cancer. Thyroid. 2007;17(4):323–31.CrossRefPubMed

47.

Andreotti C, Root JC, Schagen SB, McDonald BC, Saykin AJ, Atkinson TM, et al. Reliable change in neuropsychological assessment of breast cancer survivors. Psychooncology. 2016;25(1):43–50.CrossRefPubMed

48.

Edelstein K, Bernstein LJ. Cognitive dysfunction after chemotherapy for breast cancer. J Int Neuropsychol Soc. 2014;20(4):351–6.CrossRefPubMed

49.

Higgins JPT, Green S. 2011 Recommendations for testing of funnel plot asymmetry. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 Available at: http://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm Accessed January 31, 2019.

50.

Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8.CrossRefPubMed

Titel: Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis
verfasst von: Omar Saeed
Lori J. Bernstein
Rouhi Fazelzad
Mary Samuels
Lynn A. Burmeister
Lehana Thabane
Shereen Ezzat
David P. Goldstein
Jennifer Jones
Anna M. Sawka
Publikationsdatum: 04.04.2019
Verlag: Springer US
Erschienen in: Journal of Cancer Survivorship / Ausgabe 2/2019
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-019-00745-1

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Cognitive functioning in thyroid cancer survivors: a systematic review and meta-analysis

Abstract

Background

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Purpose

Methods

Results

Conclusions

Implications for Cancer Survivors

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Work after prostate cancer: a systematic review

Prostate cancer and subsequent nutritional outcomes: the role of diagnosis and treatment

Receipt of a survivorship care plan and self-reported health behaviors among cancer survivors

Finding sexual health aids after cancer: are cancer centers supporting survivors’ needs?

Reproductive outcomes following treatment for a gynecological cancer diagnosis: a systematic review

Adherence to American Cancer Society and American Institute of Cancer Research dietary guidelines in overweight African American breast cancer survivors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie